Clinical Trials Logo

Clinical Trial Summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder.

The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02952196
Study type Interventional
Source Centre hospitalier de l'Université de Montréal (CHUM)
Status Withdrawn
Phase Phase 2
Start date March 2019
Completion date December 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02836756 - Cannabidiol as a New Intervention for Amphetamine Dependence Phase 2
Recruiting NCT03318081 - The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction N/A
Completed NCT03221283 - The Application of Music Therapy in Female Amphetamine Use Disorder N/A
Completed NCT02285556 - The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus N/A
Recruiting NCT02713815 - Novel Intervention for Amphetamine-type Stimulants Addiction N/A
Completed NCT00713479 - An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers Phase 1
Not yet recruiting NCT02950376 - The Novel Addiction Assessment Study in Synthetic Drugs Addiction N/A